Regorafenib is a diphenylurea oral multikinase inhibitor, structurally comparable to
sorafenib, which targets a variety of kinases implicated in angiogenic and tumor growth …

Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer.
Sorafenib, regorafenib, lenvatinib and cabozantinib are tyrosine kinase inhibitors (TKIs) that …

The last 5 years have witnessed relevant advances in the systemic treatment of
hepatocellular carcinoma. New data have emerged since the development of the EASL …

Background The approval of the tyrosine kinase inhibitor sorafenib in 2007 marked a
milestone in the treatment of hepatocellular carcinoma, as sorafenib was the first systemic …

Hydrogen sulfide (H2S) is an endogenous biologically active gas produced in mammalian
tissues. It plays a very critical role in many pathophysiological processes in the body. It can …

Background: Patients with advanced hepatocellular carcinoma (HCC) typically have poor
survival outcomes. Until recently, sorafenib was the only systemic therapy option available …

Hepatocellular carcinoma (HCC) is the most common primary liver neoplasm and one of the
most common causes of death in patients with cirrhosis of the liver. In parallel with …

Regorafenib is an oral tyrosine kinase inhibitor (TKI) approved for the treatment of refractory
metastatic colorectal cancer (mCRC), advanced gastrointestinal stromal tumors (GIST) …

Simple Summary Hepatocellular carcinoma is the fourth leading cause of cancer-related
mortality worldwide and a major health problem. Overall survival is poor, with a five-year …

For a decade, sorafenib remained the only approved first-line treatment and standard of care
for advanced hepatocellular carcinoma. The treatment landscape has been evolving rapidly …